2204. High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment.
Koh J1, Kwak Y1,2, Kim J3, Kim WH1,3,4.
Cancer Res Treat. 2019 May 27. doi: 10.4143/crt.2019.195. [Epub ahead of print]Link
2203. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma.
Lee JJ1, Park S2, Park H3, Kim S4, Lee J5, Lee J6, Youk J2, Yi K2, An Y3, Park IK7, Kang CH7, Chung DH4, Kim TM8, Jeon YK9, Hong D5, Park PJ10, Ju YS11, Kim YT12.
Cell. 2019 Jun 13;177(7):1842-1857.e21. doi: 10.1016/j.cell.2019.05.013. Epub 2019 May 30.Link
2202. Impact of smoking on thyroid gland: dose-related effect of urinary cotinine levels on thyroid function and thyroid autoimmunity.
Kim SJ, Kim MJ, Yoon SG, Myong JP, Yu HW, Chai YJ, Choi JY, Lee KE.
2200. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Kim YJ1, Keam B2, Ock CY3, Song S4, Kim M3, Kim SH1, Kim KH5, Kim JS5, Kim TM6, Kim DW6, Lee JS1, Heo DS6.
Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.Link
2199. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Kim R1, Keam B2, Hahn S3, Ock CY1, Kim M1, Kim TM4, Kim DW4, Heo DS4.